YU6502A - Usmeravanje multimernih agenasa za dobijanje kontrasta pri dijagnostičkom snimanju putem multilokusnog vezivanja - Google Patents

Usmeravanje multimernih agenasa za dobijanje kontrasta pri dijagnostičkom snimanju putem multilokusnog vezivanja

Info

Publication number
YU6502A
YU6502A YU6502A YUP6502A YU6502A YU 6502 A YU6502 A YU 6502A YU 6502 A YU6502 A YU 6502A YU P6502 A YUP6502 A YU P6502A YU 6502 A YU6502 A YU 6502A
Authority
YU
Yugoslavia
Prior art keywords
compounds
relates
moieties
binding
iems
Prior art date
Application number
YU6502A
Other languages
English (en)
Inventor
Randall B. Lauffer
Thomas J. Mcmurry
Stephane Dumas
Andrew Kolodziej
John Amedio
Peter Caravan
Zhaoda Zhang
Shrikumar Nair
Original Assignee
Epix Medical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Medical Inc. filed Critical Epix Medical Inc.
Publication of YU6502A publication Critical patent/YU6502A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Predmetni pronalazak se odnosi na agense za ostvarivanje kontrasta pri dijagnostickom snimanju. Posebno, predmetni pronalazak se odnosi na nova multimerna jedinjenja koja pokazuju povecanu relaksivost nakon vezivanja za endogene proteine ili druga fizioloski relevantna mesta. Ova jedinjenja se sastoje od: a) dva ili vise hemijskih ostataka za poboljsavanje snimka (IEM-ova) (ili hemijskih ostataka za generisanje signala) koji sadrze visestruke podjedinice, b) dva ili vise hemijskih ostataka za vezivanje za ciljnu strukturu (TBM-ova) koji obezbedjuju in vivo lokalizaciju i ucvrscavanje multimera, c) hemijsku skeletnu strukturu za vezivanje gore pomenutih ostataka i d) opcione veznike za vezivanje IEM-ova za skeletnu strukturu. Predmetni pronlazak se takodje odnosi na farmaceutske preparate koji sadrze ova jedinjenja i na postupke upotrebe ovih jedinjenja i preparata za kontrastno pojacavanje tokom snimanja.
YU6502A 1999-07-29 2000-07-28 Usmeravanje multimernih agenasa za dobijanje kontrasta pri dijagnostičkom snimanju putem multilokusnog vezivanja YU6502A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14641499P 1999-07-29 1999-07-29
US16365099P 1999-11-04 1999-11-04

Publications (1)

Publication Number Publication Date
YU6502A true YU6502A (sh) 2005-06-10

Family

ID=26843871

Family Applications (1)

Application Number Title Priority Date Filing Date
YU6502A YU6502A (sh) 1999-07-29 2000-07-28 Usmeravanje multimernih agenasa za dobijanje kontrasta pri dijagnostičkom snimanju putem multilokusnog vezivanja

Country Status (20)

Country Link
US (2) US6652835B1 (sh)
EP (1) EP1210124A2 (sh)
JP (2) JP2003505519A (sh)
KR (1) KR20020057946A (sh)
CN (2) CN1626246A (sh)
AU (1) AU6386000A (sh)
BR (1) BR0013171A (sh)
CA (1) CA2384565A1 (sh)
CZ (1) CZ2002343A3 (sh)
EA (1) EA200200220A1 (sh)
HK (1) HK1048952A1 (sh)
HU (1) HUP0202635A3 (sh)
IL (1) IL147854A0 (sh)
IS (1) IS6241A (sh)
MX (1) MXPA02001017A (sh)
NO (1) NO20020474L (sh)
NZ (1) NZ517017A (sh)
PL (1) PL353336A1 (sh)
WO (1) WO2001008712A2 (sh)
YU (1) YU6502A (sh)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW319763B (sh) * 1995-02-01 1997-11-11 Epix Medical Inc
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
WO1999025389A2 (en) 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
EP1203026A4 (en) * 1999-07-29 2005-03-16 Dyax Corp FRACTIONS BINDING FIBRIN
AU6386000A (en) 1999-07-29 2001-02-19 Epix Pharmaceuticals, Inc. Targeting multimeric imaging agents through multilocus binding
US6673333B1 (en) 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
AU2001276956A1 (en) 2000-07-17 2002-01-30 California Institute Of Technology Macrocyclic mri contrast agents
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
TWI284539B (en) 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
AU2002353823A1 (en) * 2001-10-16 2003-04-28 Epix Medical, Inc. Detection and treatment of intravascular lesions
US7504364B2 (en) * 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
US20060057625A1 (en) * 2002-09-16 2006-03-16 Carlson Robert E Scaffold-based artificial receptors and methods
US20060051802A1 (en) * 2002-09-16 2006-03-09 Receptors Llc Artificial receptors, building blocks, and methods
US20050037429A1 (en) * 2003-03-28 2005-02-17 Receptors Llc Artificial receptors including reversibly immobilized building blocks and methods
US20050037381A1 (en) * 2002-09-16 2005-02-17 Receptors Llc Artificial receptors, building blocks, and methods
US20050136483A1 (en) * 2003-09-03 2005-06-23 Receptors Llc Nanodevices employing combinatorial artificial receptors
US7469076B2 (en) * 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
US20040137481A1 (en) * 2002-09-16 2004-07-15 Receptors Llc Artificial receptor building blocks, components, and kits
EP1613737A4 (en) * 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
CA2526760A1 (en) * 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
DE10325752A1 (de) * 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lektin-Konjugate
AR047692A1 (es) * 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
CA2445420A1 (en) 2003-07-29 2005-01-29 Invitrogen Corporation Kinase and phosphatase assays
US7619059B2 (en) 2003-07-29 2009-11-17 Life Technologies Corporation Bimolecular optical probes
US7557577B2 (en) * 2003-12-08 2009-07-07 Siemens Aktiengesselschaft Water-soluble paramagnetic substance reducing the relaxation time of the coolant in an MRI system
WO2005079274A2 (en) * 2004-02-12 2005-09-01 Mount Sinai School Of Medicine Magnetic resonance imaging of atherosclerotic plaque
US7884052B2 (en) * 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
WO2006027244A2 (en) * 2004-09-10 2006-03-16 Bracco Imaging S.P.A. Paramagnetic metal polyamino complexes for mri visualization of internalized polynucleotides
US7985715B2 (en) 2004-09-11 2011-07-26 Receptors Llc Combinatorial artificial receptors including peptide building blocks
WO2006056227A1 (en) * 2004-11-27 2006-06-01 Eberhard-Karls- Universität Tübingen Universitätsklinikum Conjugates comprising the active agent and flanking or branched-chain peptides
DE102004062258B3 (de) * 2004-12-23 2006-01-05 Schering Ag Hydroxypyridinon-Derivate, deren Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
BRPI0519754A2 (pt) 2005-01-13 2009-03-10 Cinv Ag materiais compàsitos contendo nanopartÍculas de carbono
US20060275217A1 (en) * 2005-05-06 2006-12-07 Caravan Peter D Chemical exchange saturation transfer contrast agents
CA2614486C (en) * 2005-07-13 2014-09-16 Georgia State University Research Foundation, Inc. Contrast agent comprising a scaffold protein and a metal ion chelating site integrated therein
BRPI0617450A2 (pt) * 2005-10-18 2011-07-26 Cinv Ag partÍculas de termocura e mÉtodos para produÇço das mesmas
EP2221385A3 (en) 2005-10-28 2010-12-01 Life Technologies Corporation Deubiquination assays
US8034898B2 (en) 2005-12-29 2011-10-11 Collagen Medical, LLC Methods of collagen imaging
EP2053968A4 (en) * 2006-08-17 2015-10-21 Epix Pharm Inc METHOD FOR ILLUMINATING THE LYMPH SYSTEM
EP2156186A4 (en) * 2007-05-03 2010-11-03 Tethys Bioscience Inc BINDING REAGENTS WITH SMALL EPITOP BINDING MOLECULES
DE102007028090A1 (de) 2007-06-12 2008-12-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Aktivierbare diagnostische und therapeutische Verbindung
US8344158B2 (en) * 2007-08-15 2013-01-01 Washington University Fluorescent polymethine cyanine dyes
US20090214436A1 (en) 2008-02-18 2009-08-27 Washington University Dichromic fluorescent compounds
US8765977B2 (en) 2010-03-31 2014-07-01 General Electric Company Hydroxylated contrast enhancement agents and imaging method
US8722020B2 (en) 2010-03-31 2014-05-13 General Electric Company Hydroxylated contrast enhancement agents
US8362281B2 (en) 2010-03-31 2013-01-29 General Electric Company Intermediates for hydroxylated contrast enhancement agents
EP2806781B1 (en) 2012-01-23 2018-03-21 Washington University Goggle imaging systems and methods
US9849201B2 (en) 2013-05-03 2017-12-26 Washington University Homing agents
US10806804B2 (en) 2015-05-06 2020-10-20 Washington University Compounds having RD targeting motifs and methods of use thereof
US10301358B2 (en) 2015-06-29 2019-05-28 Collagen Medical, LLC Collagen imaging compositions
US10835623B2 (en) 2015-08-13 2020-11-17 The General Hospital Corporation Manganese-based chelate conjugates for molecular MR imaging
AU2018214596A1 (en) * 2017-02-02 2019-08-08 The University Of Akron Functionalized poly(propylene fumarate) polymers made by ring opening polymerization using magnesium catalysts
EP4072598A4 (en) 2019-12-13 2024-02-21 Washington University Near infrared fluorescent dyes, formulations and related methods

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880008A (en) 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4777957A (en) * 1985-06-14 1988-10-18 General Electric Company Method for measuring and imaging fluid flow
WO1987002893A1 (en) * 1985-11-18 1987-05-21 Board Of Regents, The University Of Texas System Polychelating agents for image and spectral enhancement (and spectral shift)
EP0271180B2 (en) 1986-08-18 1997-06-18 The Dow Chemical Company Starburst conjugates
US5011686A (en) * 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
GB8808305D0 (en) * 1988-04-08 1988-05-11 Nycomed As Compositions
US5914095A (en) * 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
GB9320277D0 (en) 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
EP0497926B1 (en) 1989-10-23 1998-06-03 Nycomed Salutar, Inc. Multi-site metal chelating agents
US5631329A (en) 1990-08-27 1997-05-20 Dendritech, Inc. Process for producing hyper-comb-branched polymers
AU660033B2 (en) * 1991-05-23 1995-06-08 Imarx Pharmaceutical Corp. Liposoluble compounds for magnetic resonance imaging
JP2894879B2 (ja) * 1991-10-04 1999-05-24 日本メジフィジックス株式会社 診断用造影剤
US5522390A (en) * 1991-11-21 1996-06-04 U.S. Philips Corporation Magnetic resonance imaging method
US5637759A (en) 1992-07-30 1997-06-10 The Regents Of The University Of California Metal-ligating amino acid derivatives for MRI and for peptide synthesis
CA2145847A1 (en) 1992-10-02 1994-04-14 Richard T. Dean Multimeric polyvalent antithrombotic agents
US5726304A (en) 1992-10-30 1998-03-10 The University Of British Columbia Porphocyanine and CNC-expanded porphyrins
US5401493A (en) * 1993-03-26 1995-03-28 Molecular Biosystems, Inc. Perfluoro-1H,-1H-neopentyl containing contrast agents and method to use same
US5579767A (en) * 1993-06-07 1996-12-03 Prince; Martin R. Method for imaging abdominal aorta and aortic aneurysms
GB9314499D0 (en) * 1993-07-12 1993-08-25 Nycomed Imaging As Method
GB9318550D0 (en) 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
DE4344460A1 (de) 1993-12-22 1995-06-29 Schering Ag Metallkomplexe von dendrimeren Makromolekülen, diese enthaltende diagnostische Mittel sowie Verfahren zur Herstellung der Komplexe und Mittel
IT1270994B (it) 1994-03-18 1997-05-26 Bracco Spa Macromolecole ramificate a struttura poliossialchilica e loro usi
WO1995027705A1 (en) 1994-04-08 1995-10-19 Bracco International B.V. Aromatic amide compounds and metal chelates thereof
GB9407812D0 (en) 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
DE4425857A1 (de) * 1994-07-07 1996-01-11 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zur ihrer Herstellung und diese enthaltende pharmazeutische Mittel
WO1998053855A1 (en) * 1997-05-30 1998-12-03 Alliance Pharmaceutical Corp. Methods and apparatus for monitoring and quantifying the movement of fluid
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
TW319763B (sh) 1995-02-01 1997-11-11 Epix Medical Inc
DE19518222A1 (de) 1995-05-11 1996-11-14 Schering Ag Verwendung von polymeren Kontrastmittel mittleren Molekulargewichts zur Differenzierung von benignen und malignen Tumoren mittels moderner bildgebender Verfahren
DE19521945A1 (de) 1995-06-12 1996-12-19 Schering Ag Kaskadenpolymere mit Iodaromaten
DE19525924A1 (de) 1995-07-04 1997-01-09 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5919442A (en) 1995-08-11 1999-07-06 Dendritech, Inc. Hyper comb-branched polymer conjugates
IT1277596B1 (it) 1995-09-15 1997-11-11 Bracco Spa Composti macromolecolari di tipo dendrimerico
US6638508B2 (en) * 1995-12-21 2003-10-28 Yeda Research And Development Co., Ltd. Modified avidin-type molecules as targeting agents for the liver and cells of the reticuloendothelial system
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
PT907379E (pt) 1996-04-01 2004-09-30 Epix Medical Inc Agentes de contraste bioactivados para imagiologia de diagnostico
WO1997041856A1 (en) 1996-05-08 1997-11-13 Massachusetts Institute Of Technology ORGANOMETALLIC LIGANDS FOR THE LOCALIZATION AND QUANTIFICATION OF AMYLOID IN VIVO AND $i(IN VITRO)
DE19641197C2 (de) * 1996-09-24 1999-02-18 Schering Ag Ionenpaare und ihre Verwendung als Kontrastmittel
NZ500273A (en) * 1997-03-18 2001-12-21 Nihon Schering Kabushiki Kaish Gadolinium (Gd) polymer MRI contrast agent responsive to environmental changes
DE19731300C1 (de) * 1997-07-11 1999-01-21 Schering Ag Perfluoralkylgruppenhaltige Trijodaromaten, Verfahren zu deren Herstellung und deren Verwendung als Kontrastmittel
US6073042A (en) * 1997-09-25 2000-06-06 Siemens Medical Systems, Inc. Display of three-dimensional MRA images in which arteries can be distinguished from veins
WO1999025389A2 (en) * 1997-11-17 1999-05-27 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US6112112A (en) * 1998-09-18 2000-08-29 Arch Development Corporation Method and system for the assessment of tumor extent in magnetic resonance images
US6342598B1 (en) * 1998-11-26 2002-01-29 Bracco International B.V. Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US6399578B1 (en) * 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
AU6386000A (en) 1999-07-29 2001-02-19 Epix Pharmaceuticals, Inc. Targeting multimeric imaging agents through multilocus binding
EP1203026A4 (en) * 1999-07-29 2005-03-16 Dyax Corp FRACTIONS BINDING FIBRIN
EP1379885A4 (en) * 2001-01-05 2005-07-06 Univ Duke CONTRAST REINFORCING AGENT FOR MAGNETIC RESONANCE IMAGING
US6459264B1 (en) * 2001-02-22 2002-10-01 Mayo Foundation For Medical Education And Research Real-time embedded magnetic resonance fluoroscopy
US20040204561A1 (en) * 2002-08-06 2004-10-14 Ellison Jeffrey J. Peptide aggregates

Also Published As

Publication number Publication date
US20040005274A1 (en) 2004-01-08
NO20020474L (no) 2002-03-27
HUP0202635A3 (en) 2006-03-28
IL147854A0 (en) 2002-08-14
PL353336A1 (en) 2003-11-17
WO2001008712A2 (en) 2001-02-08
KR20020057946A (ko) 2002-07-12
BR0013171A (pt) 2002-05-28
CA2384565A1 (en) 2001-02-08
EA200200220A1 (ru) 2002-08-29
NO20020474D0 (no) 2002-01-29
NZ517017A (en) 2004-05-28
HUP0202635A2 (hu) 2002-11-28
WO2001008712A3 (en) 2002-03-14
IS6241A (is) 2002-01-18
JP2003505519A (ja) 2003-02-12
AU6386000A (en) 2001-02-19
MXPA02001017A (es) 2002-08-12
CN1382062A (zh) 2002-11-27
JP2003201258A (ja) 2003-07-18
CN1626246A (zh) 2005-06-15
CZ2002343A3 (cs) 2002-08-14
EP1210124A2 (en) 2002-06-05
HK1048952A1 (zh) 2003-04-25
US6652835B1 (en) 2003-11-25

Similar Documents

Publication Publication Date Title
YU6502A (sh) Usmeravanje multimernih agenasa za dobijanje kontrasta pri dijagnostičkom snimanju putem multilokusnog vezivanja
WO1998018497A3 (en) Contrast agents
IL125895A0 (en) The use of an image enhancing moiety in the preparation of bioactivated nmr or optical imaging contrat agent from a prodrug
US11780882B2 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
MY128089A (en) Diagnostic imaging contrast agents with extended blood retention
MXPA04000173A (es) Compuestos basados en peptidos.
WO2006017619A3 (en) Receptor-binding cyclic peptides and methods of use
EP1342476A3 (en) FGFR3 as a marker for mesenchymal skeletal progenitor cells and use of cytotoxic conjugates comprising an FGFR3 binding agent for the treatment of cartilagineous bony tumours
WO2003049684A3 (en) Pseudo-antibody constructs
Barone et al. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line
WO1998018496A3 (en) Contrast agents
WO2008036147A3 (en) Drug delivery with stimulus responsive biopolymers
WO2002036161A3 (en) Novel targeted compositions for diagnostic and therapeutic use
WO2001077145A3 (en) Integrin binding peptide derivatives
AU2002303181A1 (en) Morpholino imaging and therapy
CA2305597A1 (en) Affinity markers for human serum albumin
WO2001082864A3 (en) 18f-labeled choline analogs
WO2004006833A3 (en) Bowel cleansing composition
AU2002350950A1 (en) Compounds for imaging alzheimer's disease
AU4546996A (en) Liposome suspensions as blood pool imaging contrast agents
WO2001052906A3 (en) Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
US20090203877A1 (en) X-ray-dense conjugate
AU1174400A (en) Retro-inversion peptides that target git transport receptors and related methods
WO2001040239A3 (en) Transition metal-cyclopentadienyl-tropane conjugates
WO2006074799A3 (en) 5-pyrrolidinylsulfonyl isatin derivatives